Aduro Biotech, Inc. (ADRO)
(Delayed Data from NSDQ)
$4.26 USD
+0.11 (2.65%)
Updated May 3, 2019 04:00 PM ET
After-Market: $4.27 (%) 5:22 PM ET
NA Value
NA Growth NA Momentum NA VGMWe use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$4.26 USD
+0.11 (2.65%)
Updated May 3, 2019 04:00 PM ET
After-Market: $4.27 (%) 5:22 PM ET
NA Value
NA Growth NA Momentum NA VGM
Zacks News
Is iShares Emerging Markets Dividend ETF (DVYE) a Strong ETF Right Now?
by Zacks Equity Research
Smart Beta ETF report for DVYE
Is iShares Emerging Markets Dividend ETF (DVYE) a Strong ETF Right Now?
by Zacks Equity Research
Smart Beta ETF report for DVYE
Is iShares Emerging Markets Dividend ETF (DVYE) a Strong ETF Right Now?
by Zacks Equity Research
Smart Beta ETF report for DVYE
Aduro Biotech (ADRO) Reports Q2 Loss, Tops Revenue Estimates
by Zacks Equity Research
Aduro Biotech (ADRO) delivered earnings and revenue surprises of -10.53% and 76.06%, respectively, for the quarter ended June 2020. Do the numbers hold clues to what lies ahead for the stock?
Aduro Biotech (ADRO) May Report Negative Earnings: Know the Trend Ahead of Q2 Release
by Zacks Equity Research
Aduro Biotech (ADRO) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Aduro Biotech's Shares March Higher, Can It Continue?
by Zacks Equity Research
As of late, it has definitely been a great time to be an investor in Aduro Biotech.
Aduro Biotech (ADRO) Upgraded to Buy: What Does It Mean for the Stock?
by Zacks Equity Research
Aduro Biotech (ADRO) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
Is Aduro Biotech (ADRO) Outperforming Other Medical Stocks This Year?
by Zacks Equity Research
Is (ADRO) Outperforming Other Medical Stocks This Year?
Is Aduro Biotech (ADRO) Stock a Solid Choice Right Now?
by Zacks Equity Research
Aduro Biotech (ADRO) has seen solid earnings estimate revision activity over the past month, and belongs to a strong industry as well.
Aduro Biotech (ADRO) Reports Q1 Loss, Tops Revenue Estimates
by Zacks Equity Research
Aduro Biotech (ADRO) delivered earnings and revenue surprises of 18.18% and 58.34%, respectively, for the quarter ended March 2020. Do the numbers hold clues to what lies ahead for the stock?
Aduro Biotech (ADRO) May Report Negative Earnings: Know the Trend Ahead of Q1 Release
by Zacks Equity Research
Aduro Biotech (ADRO) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Is Aduro Biotech (ADRO) Outperforming Other Medical Stocks This Year?
by Zacks Equity Research
Is (ADRO) Outperforming Other Medical Stocks This Year?
Aduro Biotech (ADRO) Down 3.1% Since Last Earnings Report: Can It Rebound?
by Zacks Equity Research
Aduro Biotech (ADRO) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
4 Cheap Stocks to Buy on Signs of Coronavirus Slowdown
by Shuvra Shankar Dey
The highly oversold market offers some ultra-cheap stocks with stellar prospects as the coronavirus pandemic shows signs of slowing down.
Aduro Biotech (ADRO) Gains As Market Dips: What You Should Know
by Zacks Equity Research
Aduro Biotech (ADRO) closed the most recent trading day at $2.54, moving +1.2% from the previous trading session.
Has Aduro Biotech (ADRO) Outpaced Other Medical Stocks This Year?
by Zacks Equity Research
Is (ADRO) Outperforming Other Medical Stocks This Year?
4 Ultra-Cheap Stocks to Abate Coronavirus-Led Investment Agony
by Shuvra Shankar Dey
We have picked stocks that trade under $10 with stellar bottom-line projections, positive estimate revisions and impressive share-price rally, indicating momentum in the mid-term.
Aduro Biotech (ADRO) Gains As Market Dips: What You Should Know
by Zacks Equity Research
Aduro Biotech (ADRO) closed at $2.53 in the latest trading session, marking a +1.2% move from the prior day.
Is Aduro Biotech (ADRO) Outperforming Other Medical Stocks This Year?
by Zacks Equity Research
Is (ADRO) Outperforming Other Medical Stocks This Year?
PDL BioPharma (PDLI) Misses on Q4 Earnings, To Dissolve by Year-End
by Zacks Equity Research
PDL BioPharma's (PDLI) earnings lag estimates in the fourth quarter. The company announces plan to complete liquidation by the end of 2020.
Aduro's (ADRO) Earnings & Revenues Miss Estimates in Q4
by Zacks Equity Research
Aduro (ADRO) incurs wider-than-expected loss in Q4. Revenues too fall short of the mark.
Aduro Biotech (ADRO) Reports Q4 Loss, Lags Revenue Estimates
by Zacks Equity Research
Aduro Biotech (ADRO) delivered earnings and revenue surprises of -14.29% and -26.61%, respectively, for the quarter ended December 2019. Do the numbers hold clues to what lies ahead for the stock?
Aduro Biotech (ADRO) Stock Moves -0.6%: What You Should Know
by Zacks Equity Research
Aduro Biotech (ADRO) closed the most recent trading day at $3.33, moving -0.6% from the previous trading session.
AMAG Q4 Loss Wider Than Expected, Revenues Beat Estimates
by Zacks Equity Research
AMAG (AMAG) posts a wider-than-expected loss and beats sales estimates in the fourth quarter of 2019.
5 Reasons to Buy These Small-Cap Stocks Now
by Sanghamitra Saha
After a painful stretch, small-cap U.S. stocks should rebound on a few tailwinds.